Abstract
The ancient Chinese medical literature, as well as our prior clinical experience, suggests that fecal microbiota transplantation (FMT) could treat the inflammatory mass. We aimed to evaluate the efficacy and safety of multiple fresh FMTs for Crohn’s disease (CD) complicated with intraabdominal inflammatory mass. The "one-hour FMT protocol" was followed in all patients. Twenty-five patients were diagnosed with CD and related inflammatory mass by CT or MRI. All patients received the initial FMT followed by repeated FMTs every 3 months. The primary endpoint was clinical response (improvement and remission) and sustained clinical remission at 12 months. Secondary endpoints were improvement in size of phegmon/abscess based upon cross-sectional imaging and safety of FMT. 68.0% (17/25) and 52.0% (13/25) of patients achieved clinical response and clinical remission at 3 months post the initial FMT, respectively. The proportion of patients at 6 months, 12 months and 18 months achieving sustained clinical remission with sequential FMTs was 48.0% (12/25), 32.0% (8/25) and 22.7% (5/22), respectively. 9.5% (2/21) of patients achieved radiological healing and 71.4% (15/21) achieved radiological improvement. No severe adverse events related to FMT were observed. This pragmatic study suggested that sequential fresh FMTs might be a promising, safe and effective therapy to induce and maintain clinical remission in CD with intraabdominal inflammatory mass.
Highlights
Crohn’s disease (CD) is characterized by a transmural inflammatory process, which may lead to the formation of intraabdominal inflammatory masses[1, 2]
25 CD patients complicated with intraabdominal inflammatory mass were analyzed in this study (Table 1)
The treatment of intraabdominal inflammatory masses associated with CD is a clinical challenge
Summary
Crohn’s disease (CD) is characterized by a transmural inflammatory process, which may lead to the formation of intraabdominal inflammatory masses (phlegmon or abscess)[1, 2]. Given concerns regarding postoperative recurrence of Crohn’s disease and short bowel syndrome resulting from multiple surgical operations, surgical treatment is considered as a last resort. Another particular dilemma for clinicians is whether to continue immunosuppressive therapies for severely active patients in the setting of an inflammatory mass because of the increased risk of abdominal infection[1,2,3,4]. The management of refractory CD complicated with intraabdominal inflammatory mass is challenging.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.